GAGLIARDI, GLORIA
GAGLIARDI, GLORIA
Universita' degli Studi di MILANO
Concomitant diagnosis of sexually transmitted infections and human monkeypox in patients attending a sexual health clinic in Milan, Italy
2023 A. Rizzo, G. Pozza, F. Salari, A. Giacomelli, D. Mileto, M.V. Cossu, A. Mancon, G. Gagliardi, M. Bianchi, V. Micheli, A. Capetti, S. Antinori, M.R. Gismondo, P. Olivieri, A. Lombardi
Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects
2022 F. Borgonovo, C.A. Stangalini, C. Tinelli, C. Mariani, D. Mileto, M.V. Cossu, L. Abbati, L. Bilardo, G. Gagliardi, M. Cutrera, M. Pellicciotta, L. Armiento, G. Dedivitiis, A.F. Capetti, G. Rizzardini
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics
2023 C. Candela, A.R. Raccagni, E. Bruzzesi, C. Bertoni, A. Rizzo, G. Gagliardi, D. Canetti, N. Gianotti, D. Mileto, M.R. Gismondo, A. Castagna, S. Nozza
Immune Response and Transplacental Antibody Transfer in Pregnant Women after COVID-19 Vaccination
2023 C. Lubrano, A. Mancon, G.M. Anelli, G. Gagliardi, R. Corneo, M. Bianchi, C. Coco, G. DAL MOLIN, M. Vignali, I. Schirripa, N. Di Simone, G. Pavone, A. Pellegrino, M.R. Gismondo, V.M. Savasi, I. Cetin
One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG
2021 A.F. Capetti, F. Borgonovo, D. Mileto, G. Gagliardi, C. Mariani, A. Lupo, G. Dedivitiis, P. Meraviglia, M. Pellicciotta, L. Armiento, M.V. Cossu, G. Rizzardini
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson’s Disease and Atypical Parkinsonisms
2020 S. Mazzetti, M. De Leonardis, G. Gagliardi, A.M. Calogero, M.J. Basellini, L. Madaschi, I. Costa, F. Cacciatore, S. Spinello, M. Bramerio, R. Cilia, C. Rolando, G. Giaccone, G. Pezzoli, G. Cappelletti
Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: A cross-sectional study: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine
2021 L. Pezzati, A. Giacomelli, D. Mileto, F. Conti, G. Gagliardi, A. Rizzo, L. Milazzo, M. Schiuma, A. Covizzi, M. Siano, C. Bassoli, M. Passerini, M. Piscaglia, A. Torre, L. Oreni, G. Rizzardini, M. Galli, A.L. Ridolfo, S. Antinori
Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
2022 D. Mileto, V. Micheli, C. Fenizia, M. Cutrera, G. Gagliardi, A. Mancon, F. Bracchitta, A. De Silvestri, G. Rizzardini, A. Lombardi, M. Biasin, M.R. Gismondo
SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response
2021 D. Mileto, C. Fenizia, M. Cutrera, G. Gagliardi, A. Gigantiello, A. De Silvestri, A. Rizzo, A. Mancon, M. Bianchi, F. De Poli, M. Cuomo, I. Burgo, M. Longo, S. Rimoldi, C. Pagani, S. Grosso, V. Micheli, G. Rizzardini, M. Biasin, M. Gismondo, A. Lombardi